Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Female Infertility Market Size Forecast: How Big Could The Market Get By 2030?
The female infertility market size has exhibited consistent growth in recent years. It is forecast to increase from $1.86 billion in 2025 to $1.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.1%. In the past, this market expansion can be ascribed to trends such as delayed childbearing, a greater understanding of infertility, the accessibility of fertility drugs, the establishment of more reproductive health clinics, and enhancements in diagnostic imaging.
The female infertility market is projected to experience consistent expansion over the upcoming years. This market is forecast to reach $2.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.8%. Factors driving this expansion during the forecast period include enhanced fertility drug developments, the rise of individualized fertility care, greater uptake of AI-powered fertility monitoring, the broadening scope of fertility tourism, and increasing capital directed towards reproductive health. Key trends anticipated for the forecast period encompass a surge in demand for assisted reproductive technologies, a heightened emphasis on hormonal and ovulation therapies, the increasing application of sophisticated diagnostic methods, the proliferation of fertility clinics and related services, and the incorporation of digital platforms into fertility management.
Get A Free Sample Report With In-Depth Market Insights:
Female Infertility Market Growth Backed By Core Demand Fundamentals
The rising occurrence of infertility is projected to fuel the expansion of the female infertility market in the future. Infertility is defined as the inability to achieve pregnancy following 12 months of consistent, unprotected sexual activity. The escalating rates of infertility stem from elements such as postponed childbearing, shifts in lifestyle, exposure to environmental toxins, a surge in obesity, and elevated stress levels. Addressing and managing underlying medical, hormonal, or structural conditions that hinder fertility necessitates female infertility treatment, thereby boosting the likelihood of conception and averting irreversible infertility. For example, in April 2023, the World Health Organization, a Switzerland-based intergovernmental body, reported that roughly 17.5% of the worldwide adult population, equivalent to approximately 1 in 6 people, experience infertility. Consequently, the growing incidence of infertility is a key factor driving the development of the female infertility market.
Female Infertility Market Segment Breakdown: Which Categories Lead On Revenue?
The female infertility market covered in this report is segmented –
1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate
2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)
3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin
4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole
5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine
#Female Infertility Market Growth Trends: What’s Shaping The Future Outlook?
Key enterprises within the female infertility market are concentrating on developing innovative products, such as non-invasive diagnostic tests, to secure a competitive advantage in the sector. A noninvasive diagnostic test is a medical procedure that identifies conditions or diseases without requiring surgical intervention or penetration of the body. For instance, in August 2024, Heranova Lifesciences, a US-based biotech company, launched an early access program for HerResolve, a non-invasive diagnostic test specifically for endometriosis. Endometriosis impacts approximately 200 million women worldwide, manifesting symptoms like infertility, pain, and bleeding. For many women, obtaining an accurate diagnosis typically requires an average of 7-10 years from the initial appearance of symptoms, primarily due to the diverse presentation of symptoms and the invasive character of the most reliable diagnostic technique, exploratory laparoscopic surgery. HerResolve offers the potential to reduce this diagnostic waiting period from years to months, which would lead to improved patient and healthcare outcomes. HerResolve aims to significantly shorten this timeline, thereby enhancing patient care and overall results.
Female Infertility Market Leading Players And Competitive Positioning
Major companies operating in the female infertility market are Pfizer Inc, Merck And Co Inc, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Organon Theramex, Juniper Reproductive Health Ltd, Ferring Pharmaceuticals, Mankind Pharma, ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Merck KGaA, Gedeon Richter Plc, Novartis AG, AbbVie Inc, Ipsen, Theramex, Vitrolife AB, Conceivable Life Sciences, AIVF
View The Full Female Infertility Market Report:
Female Infertility Market Geographic Analysis: Where Is Demand Rising Fastest?
Europe was the largest region in the female infertility market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
